Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

Disease Specific Inclusion Criteria

Group A (patients with measurable disease) Relapsed/Refractory Hodgkin Lymphoma (HL) and Diffuse Large B cell Lymphoma (DLBCL) DLBCL

* Patients who have failed at least 2 lines of prior therapy with a failed attempt at both an autologous stem cell transplant and chimeric antigen receptor T cell therapy.
* Patients who are deemed autologous stem cell transplant ineligible and have failed only one line of prior therapy.
* Systemic therapies to treat prior indolent lymphomas count towards previous DLBCL lines of therapy unless the treatment was anti-CD20 antibody monotherapy.

HL

* Rel/ref HL failing more than or equal to 1 salvage regimens, including prior Brentuximab Vedotin (BV)
* Rel/ref after autologous HSCT

Group B (consolidation after auto-HSCT for patients at high risk for relapse) DLBCL

* Patients with \< CMR/CR (by PET/CT) with initial treatment regimen
* Patients with relapse \<12 months from diagnosis or \<6 months from completion of initial therapy
* Patients with \<CMR/CR (by PET/CT) prior to autologous HSCT
* Patients requiring \>1 salvage regimen prior to autologous HSCT HL
* Patients with relapse \<12 months from diagnosis or \<6 months from completion of initial therapy
* Patients with \<CMR/CR (by PET/CT) prior to autologous HSCT
* Patients requiring \>1 salvage regimen prior to autologous HSCT

Recipient Inclusion Criteria for Initial and Subsequent Procurements (TAA-T Cell Generation):

* Age \>12 years
* Karnofsky/Lansky score of more than or equal to 50 (see appendix C).
* ALC \> 600
* Patients receiving Granulocyte colony-stimulating factor (G-CSF) are recommended a washout period of a minimum of two weeks before procurement
* Agree to use contraceptive measures during study protocol participation (when age appropriate)
* Patient or parent/guardian capable of providing informed consent

Recipient Exclusion Criteria for Initial and Subsequent Procurements (TAA-T Cell Generation):

* Prior allogeneic BMT
* Prior solid organ transplant
* Patient who has received ATG, Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollment
* Patient with uncontrolled infections
* Patient with active HIV
* Pregnancy or lactating
* Failure to meet institutional guidelines for treatment with Nivolumab

Recipient Inclusion Criteria for Initial and Subsequent TAA-T Cell Infusions:

* Age \>12 years
* Patient has received at least 8 weeks of Nivolumab
* Patients with Grade 1 toxicities attributed to Nivolumab will be eligible at the discretion of the PI. Toxicities include but not limited to: laboratory abnormalities in thyroid function tests suggestive of hypothyroidism, thyroiditis or thyroid dysfunction adequately managed with thyroid hormone replacement, or abnormalities in amylase, lipase
* Steroids less than 0.5 mg/kg/day prednisone or equivalent
* Karnofsky/Lansky score of more than or equal to 50
* Pulse oximetry of \> 90% on room air
* Bilirubin less than or equal to 2.5 mg/dL, AST/ALT less than or equal to 5x upper limit of normal, serum creatinine \< 1.0 or 2x the upper limit of normal (whichever is higher)
* Absolute neutrophil count \> 250/µL (may be supported with GCSF)
* Agree to use contraceptive measures during study protocol participation (when age appropriate)
* Patient or parent/guardian capable of providing informed consent

Recipient Exclusion Criteria for Initial and Subsequent TAA-T Cell Infusions:

* Investigational therapies within 28 days prior to screening for enrollment
* Uncontrolled infections
* Patient with ≥ grade 1 or symptomatic non-hematologic toxicities from prior therapies